Ionis Pharmaceuticals (IONS) Misses Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ionis reports second quarter financial results and recent business achievements
August 9, 2022 7:00 AM EDTReported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22
Tofersen NDA under priority review, PDUFA January 25, 2023
Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen BALANCE Phase 3 studies
On track to achieve 2022 financial guidance
Webcast today, August 9, 2022, at 11:30 a.m. Eastern Time
CARLSBAD, Calif., Aug. 9, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the second quarter of 2022Â and recent business achievements.
... More